Dianthus Therapeutics (NASDAQ:DNTH) Coverage Initiated at William Blair

William Blair assumed coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research note released on Wednesday morning, Marketbeat Ratings reports. The brokerage issued an outperform rating on the stock. William Blair also issued estimates for Dianthus Therapeutics’ FY2025 earnings at ($3.26) EPS, FY2026 earnings at ($3.00) EPS, FY2027 earnings at ($2.99) EPS, FY2028 earnings at ($3.11) EPS and FY2029 earnings at ($3.81) EPS.

DNTH has been the topic of several other reports. Wedbush reaffirmed an “outperform” rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Guggenheim reaffirmed a “buy” rating and issued a $84.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Robert W. Baird dropped their target price on Dianthus Therapeutics from $58.00 to $50.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research report on Tuesday, May 13th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $53.00.

Dianthus Therapeutics Trading Up 4.0%

DNTH stock opened at $19.12 on Wednesday. The firm has a market cap of $614.74 million, a P/E ratio of -6.64 and a beta of 1.38. Dianthus Therapeutics has a 12-month low of $13.37 and a 12-month high of $32.27. The stock’s 50 day simple moving average is $18.85 and its 200 day simple moving average is $20.46.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.04. Dianthus Therapeutics had a negative return on equity of 29.26% and a negative net margin of 1,544.23%. The business had revenue of $1.16 million for the quarter, compared to analyst estimates of $0.81 million. On average, research analysts forecast that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. KLP Kapitalforvaltning AS bought a new position in shares of Dianthus Therapeutics in the fourth quarter worth $33,000. US Bancorp DE boosted its stake in Dianthus Therapeutics by 2,013.3% during the first quarter. US Bancorp DE now owns 1,585 shares of the company’s stock valued at $29,000 after buying an additional 1,510 shares in the last quarter. BNP Paribas Financial Markets bought a new position in Dianthus Therapeutics during the fourth quarter valued at about $59,000. GAMMA Investing LLC boosted its stake in Dianthus Therapeutics by 3,030.6% during the first quarter. GAMMA Investing LLC now owns 3,882 shares of the company’s stock valued at $70,000 after buying an additional 3,758 shares in the last quarter. Finally, AlphaQuest LLC boosted its stake in Dianthus Therapeutics by 273.1% during the fourth quarter. AlphaQuest LLC now owns 4,197 shares of the company’s stock valued at $91,000 after buying an additional 3,072 shares in the last quarter. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.